C9285 HCPCS Level II code: Lidocaine 70 mg/tetracaine 70 mg, per patch
C9285 is the HCPCS code for “Lidocaine 70 mg/tetracaine 70 mg, per patch” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
C9285Lidocaine 70 mg/tetracaine 70 mg, per patch
Short description: Patch, lidocaine/tetracaine
HCPCS · United States
Notes for C9285
As CMS prints them, with any note C9285 takes from the headings above it.
Note
- CMS processing note 0093: "C" CODES ARE UNIQUE TEMPORARY PRICING CODES THAT WERE INITIALLY ESTABLISHED BY CMS FOR THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM (OPPS). THE "C" CODES ARE USED ON MEDICARE OPPS CLAIMS BUT MAY ALSO BE RECOGNIZED ON CLAIMS FROM OTHER PROVIDERS OR BY OTHER PAYMENT SYSTEMS.
Medicare details
The indicators CMS publishes with C9285 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Statute
- Type of service
- Medical care
- BETOS category
- Other drugs
- Coverage statute
- 1833(t)
- Added
- Jul 1, 2011
Where C9285 sits
- 1C codesOutpatient prospective payment system
- 2Active code C9285Lidocaine 70 mg/tetracaine 70 mg, per patch
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code C9285 mean?
C9285 is the HCPCS code for “Lidocaine 70 mg/tetracaine 70 mg, per patch” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover C9285?
CMS lists C9285’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Statute”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside C9285
All C codesC9176Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study doseC9248Injection, clevidipine butyrate, 1 mgC9250Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 mlC9254Injection, lacosamide, 1 mgC9257Injection, bevacizumab, 0.25 mgC9275Injection, hexaminolevulinate hydrochloride, 100 mg, per study doseC9290Injection, bupivacaine liposome, 1 mgC9293Injection, glucarpidase, 10 unitsC9300Injection, indigotindisulfonate sodium, 1 mgC9301Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseC9302Injection, zanidatamab-hrii, 2 mgC9303Injection, zolbetuximab-clzb, 1 mg